Value of [11C]choline-Positron Emission Tomography for Re-Staging Prostate Cancer: A Comparison With [18F]fluorodeoxyglucose-Positron Emission Tomography (original) (raw)

Abstract

Purpose: We compared [ 11 C]choline-positron emission tomography (PET) with [ 18 F]fluorodeoxyglucose-PET for re-staging prostate cancer in a group of 100 patients. Materials and Methods: A total of 100 consecutive patients referred for whole body [ 18 F]fluorodeoxyglucose-PET for clinical prostate re-staging after radical treatment for prostate cancer were retrospectively included in the study. Mean prostate specific antigen (PSA) was 6.57 ng./ml. In all cases [ 11 C]choline-PET was also performed. PET studies were done with a multiring device 5 minutes after intravenous injection of approximately 370 MBq. [ 11 C]choline and 60 minutes after injection of approximately 370 MBq. [ 18 F]fluorodeoxyglucose. PET findings were compared with those obtained with different conventional imaging and with PSA assessed at the time of PET and 1 year later. Results: Areas of abnormal focal increases were noted in 47% of patients on [ 11 C]choline-PET and in 27% on [ 18 F]fluorodeoxyglucose-PET. Of the 100 patients 49 had positive conventional imaging findings. All except 14 [ 11 C]choline-PET findings were concordant with conventional imaging, including 6 negative and 8 positive conventional imaging results. All except 1 [ 11 C]choline-PET negative cases also had negative conventional imaging after 1 year. PSA at 1 year remained stable or decreased in 80% and 62% of [ 11 C]choline-PET negative and positive cases, respectively. Conclusions: [ 11 C]choline-PET seems to be useful for re-staging prostatectomy cases with increasing serum PSA levels. It is superior to [ 18 F]fluorodeoxyglucose-PET and complementary to conventional imaging but with the advantage of staging disease at a single step.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (21)

  1. Gittes, R. F.: Carcinoma of the prostate. N Engl J Med, 324: 236, 1991
  2. Sartor, C. I., Strawderman, M. H., Lin, X. H., Kish, K. E., McLaughlin, P. W. and Sandler, H. M.: Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys, 38: 941, 1997
  3. Moul, J. W.: Prostate specific antigen only progression of pros- tate cancer. J Urol, 163: 1632, 2000
  4. Silverman, J. M. and Krebs, T. L.: MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol, 168: 379, 1997
  5. Rosenthal, D. I.: Radiologic diagnosis of bone metastases. Can- cer, suppl., 80: 1595, 1997
  6. Hoh, C. K., Schiepers, C., Seltzer, M. A., Gambhir, S. S., Silverman, D. H., Czernin, J. et al: PET in oncology: will it replace the other modalities? Semin Nucl Med, 27: 94, 1997
  7. Ak, I., Stokkel, M. P. and Pauwels, E. K.: Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol, 126: 560, 2000
  8. Liu, I. J., Zafar, M. B., Lai, Y. H., Segall, G. M. and Terris, M. K.: Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology, 57: 108, 2001
  9. Hofer, C., Laubenbacher, C., Block, T., Breul, J., Hartung, R. and Schwaiger, M.: Fluorine-18-fluorodeoxyglucose positron emis- sion tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol, 36: 31, 1999
  10. Shreve, P. D., Grossman, H. B., Gross, M. D. and Wahl, R. L.: Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology, 199: 751, 1996
  11. Yeh, S. D., Imbriaco, M., Larson, S. M., Garza, D., Zhang, J. J., Kalaigian, H. et al: Detection of bony metastases of androgen- independent prostate cancer by PET-FDG. Nucl Med Biol, 23: 693, 1996
  12. Hara, T., Kosaka, N., Shinoura, N. and Kondo, T.: PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med, 38: 842, 1997
  13. Shinoura, N., Nishijima, M., Hara, T., Haisa, T., Yamamoto, H., Fujii, K. et al: Brain tumors: detection with C-11 choline PET. Radiology, 202: 497, 1997
  14. Soergel, T. M., Koch, M. O., Foster, R. S., Bihrle, R., Wahle, G., Gardner, T. et al: Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific anti- gen recurrence results after radical prostatectomy. J Urol, 166: 2198, 2001
  15. Hamacher, K., Coenen, H. H. and Stocklin, G.: Efficient ste- reospecific synthesis of no-carrier-added 2-[18F]-fluoro-2- deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med, 27: 235, 1986
  16. Kotzerke, J., Prang, J., Neumaier, B., Volkmer, B., Guhlmann, A., Kleinschmidt, K. et al: Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med, 27: 1415, 2000
  17. Hara, T., Kosaka, N. and Kishi, H.: PET imaging of prostate cancer using carbon-11-choline. J Nucl Med, 39: 990, 1998
  18. Ohtani, T., Kurihara, H., Ishiuchi, S., Saito, N., Oriuchi, N., Inoue, T. et al: Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR im- aging. Eur J Nucl Med, 28: 1664, 2001
  19. Pauwels, E. K., Sturm, E. J., Bombardieri, E., Cleton, F. J. and Stokkel, M. P.: Positron-emission tomography with [18F]flu- orodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol, 126: 549, 2000
  20. Beyer, T., Townsend, D. W., Brun, T., Kinahan, P. E., Charron, M., Roddy, R. et al: A combined PET/CT scanner for clinical oncology. J Nucl Med, 41: 1369, 2000
  21. FIG. 3. Correlation of serum PSA and [ 11 C]choline-PET body sur- face area standardized uptake (SUVbsa) in 45 of 47 positive [ 11 C]choline-PET cases. PSA values of 72 and 171 ng./ml. were omit- ted. POSITRON EMISSION TOMOGRAPHY FOR RESTAGING PROSTATE CANCER